Abbott Laboratories $ABT Shares Sold by O Shaughnessy Asset Management LLC

O Shaughnessy Asset Management LLC lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 8.5% in the fourth quarter, Holdings Channel reports. The firm owned 299,737 shares of the healthcare product maker’s stock after selling 27,804 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Abbott Laboratories were worth $37,554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories during the 4th quarter worth $25,000. Harbor Capital Advisors Inc. purchased a new position in Abbott Laboratories during the 4th quarter worth $27,000. Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories during the 3rd quarter worth $33,000. Leonteq Securities AG purchased a new position in Abbott Laboratories during the 4th quarter worth $35,000. Finally, Board of the Pension Protection Fund purchased a new position in Abbott Laboratories during the 4th quarter worth $38,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of ABT opened at $91.20 on Monday. The company has a 50-day simple moving average of $92.80 and a 200-day simple moving average of $109.16. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $158.85 billion, a PE ratio of 25.55, a P/E/G ratio of 1.52 and a beta of 0.63. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The business had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Activity

In other Abbott Laboratories news, Director Daniel J. Starks bought 10,000 shares of the company’s stock in a transaction on Monday, April 27th. The stock was purchased at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Philip P. Boudreau bought 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were acquired at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the acquisition, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Mizuho cut their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research report on Wednesday, April 22nd. The Goldman Sachs Group cut their price objective on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Argus cut their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating for the company in a report on Tuesday, April 21st. Finally, Raymond James Financial cut their price target on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories has a consensus rating of “Moderate Buy” and an average target price of $119.09.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.